MALAT1 and colorectal carcinoma: Here, we observed that serum MALAT1, PVT1, miRNA-101 and miRNA-186 were distinctively expressed between individuals with CRC and healthy control and/or non-CRC, besides being distinguished against CRC from other groups with moderate to high sensitivity and specificity, indicating serum MALAT1, PVT1, miRNA-101 and miRNA-186 as potential novel biomarkers for early and new CRC diagnosis.